Pharmaceutical Technology serves as the connection to bio manufacturing and development, featuring regulatory updates and ...

A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...

The Centers for Disease Control and Prevention (CDC) recommends that pregnant women receive an RSV vaccine during their third ...

In June, infectious disease physicians sounded the alarm over the Trump administration overstepping existing, transparent processes for changing vaccine recommendations, particularly pointing to new ...

“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...

FDA accepts GSK's application to expand Arexvy vaccine use to at-risk adults aged 18–49, with a decision expected in the ...

A new respiratory syncytial virus vaccine to protect infants from severe illness is available in South Africa's private sector but not yet in public clinics. The country's advisory group on ...

FDA accepts GSK's filing to extend Arexvy's RSV vaccine use to high-risk adults under 50, with a decision due in 2026.

GSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV) vaccine Arexvy to adults under the age of 50 who are at increased risk of the ...

The update covers the safety and appropriate timing of vaccinations, screening for osteoporosis, cervical cancer, skin cancer ...